Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants

Competing Interest Statement

C.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery and receives research support for SARS-CoV-2 studies from Abbott Laboratories. The other authors declare no competing interests.

Funding Statement

This work was funded by US CDC Epidemiology and Laboratory Capacity (ELC) for Infectious Diseases Grant 6NU50CK000539 to the California Department of Public Health (COVIDnet) (M-K.M., C.H., D.A.W., C.Y.C.), the Innovative Genomics Institute (IGI) at UC Berkeley and UC San Francisco (J.D., M.O., C.Y.C.), US Centers for Disease Control and Prevention contract 75D30121C10991 (C.Y.C.), the Roddenberry Foundation (M.O.), National Institutes of Health (NIH) grants R37AI083139 (M.O.), R21AI59666 (J.A.D.), and U54HL147127 (M.M.K.), the Howard Hughes Medical Institute (J.A.D.), the Gladstone Institutes (J.A.D. and M.O.), Abbott Laboratories (C.Y.C.), and the Sandler Program for Breakthrough Biomedical Research (C.Y.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this article are those of the author(s) and do not necessarily represent the views or opinions of the California Department of Public Health or the California Health and Human Services Agency.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board of UCSF gave ethical approval for this work Details in manuscript: Blood samples were collected through two methods. First, remnant whole blood and plasma samples from patients hospitalized with COVID-19 at UCSF were retrieved from UCSF Clinical Laboratories daily based on availability. Remnant samples were biobanked and retrospective medical chart reviews for relevant demographic and clinical metadata were performed under a waiver of consent and according to protocols approved by the UCSF Institutional Review Board (protocol numbers 10-01116 and 11-05519). Samples were obtained from pediatric and adult patients of all genders. No analyses based on sex or age were conducted. Second, plasma samples were also collected through the UMPIRE (UCSF EMPloyee and community member Immune REsponse) study, a longitudinal COVID-19 research study focused on collection of prospective whole blood and plasma samples from enrolled subjects to evaluate the immune response to vaccination, with and without boosting, and/or vaccine breakthrough infection. Informed consent for participation in the UMPIRE study and collection of data and samples were obtained according to a protocol approved by the UCSF Institutional Review Board (protocol number 20-33083).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes